A Research Study for Patients With Metastatic Renal Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2005-03-29
- Last Posted Date
- 2019-10-18
- Lead Sponsor
- Celgene
- Target Recruit Count
- 30
- Registration Number
- NCT00106613
- Locations
- 🇺🇸
University of Chicago, Chicago, Illinois, United States
🇺🇸City of Hope National Medical Center, Duarte, California, United States
🇺🇸Seattle Cancer Care Alliance, Seattle, Washington, United States
A Single Agent Phase II Study of Romidepsin (Depsipeptide, FK228) in the Treatment of Cutaneous T-cell Lymphoma (CTCL)
- Conditions
- First Posted Date
- 2005-03-25
- Last Posted Date
- 2019-10-30
- Lead Sponsor
- Celgene
- Target Recruit Count
- 102
- Registration Number
- NCT00106431
- Locations
- 🇺🇸
UCLA Jonsson Cancer Center, Los Angeles, California, United States
🇺🇸Stanford Comprehensive Cancer Center, Stanford, California, United States
🇺🇸University of Pennsylvania Abrahamson Cancer Center, Philadelphia, Pennsylvania, United States
A Research Study for Patients With Prostate Cancer
- First Posted Date
- 2005-03-25
- Last Posted Date
- 2019-11-18
- Lead Sponsor
- Celgene
- Target Recruit Count
- 35
- Registration Number
- NCT00106418
Continuation Trial Evaluating the Tolerability and Activity of FK228 in Patients That Completed Prior Study With FK228
- Conditions
- Interventions
- First Posted Date
- 2005-03-23
- Last Posted Date
- 2019-11-18
- Lead Sponsor
- Celgene
- Target Recruit Count
- 2
- Registration Number
- NCT00106301
- Locations
- 🇺🇸
University of Florida, Gainesville, Florida, United States
🇺🇸City of Hope National Medical Center, Duarte, California, United States
🇺🇸University of Chicago, Chicago, Illinois, United States
Alternative Dosing Regimens of Subcutaneous Azacitidine for Myelodysplastic Syndromes
- First Posted Date
- 2005-02-01
- Last Posted Date
- 2019-11-22
- Lead Sponsor
- Celgene
- Target Recruit Count
- 151
- Registration Number
- NCT00102687
- Locations
- 🇺🇸
Comprehensive Blood and Cancer Center, Research Department, Bakersfield, California, United States
🇺🇸Great Lakes Cancer Institute Breslin Cancer Center, Lansing, Michigan, United States
🇺🇸Greater Dayton Cancer Center, Kettering, Ohio, United States
A Safety Study of ABI-007 for In-Stent Restenosis
- Conditions
- Interventions
- First Posted Date
- 2004-10-07
- Last Posted Date
- 2019-11-18
- Lead Sponsor
- Celgene
- Target Recruit Count
- 76
- Registration Number
- NCT00093223
- Locations
- 🇺🇸
Abraxis BioScience, Inc., Durham, North Carolina, United States
Study of Albumin-bound Paclitaxel (Abraxane) in Combination With Carboplatin and Herceptin in Patients With Advanced Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2004-10-05
- Last Posted Date
- 2019-11-25
- Lead Sponsor
- Celgene
- Target Recruit Count
- 32
- Registration Number
- NCT00093145
- Locations
- 🇺🇸
Swedish Medical Center Cancer Institute Research, Seattle, Washington, United States
🇺🇸Breastlink Med Group, Long Beach, California, United States
🇺🇸Hematology/Oncology P.C. Carl & Dorothy Bennet Cancer Center, Stamford, Connecticut, United States
Trial of ABI-007 in Previously Treated Patients With Metastatic Melanoma
- Conditions
- First Posted Date
- 2004-10-04
- Last Posted Date
- 2017-04-26
- Lead Sponsor
- Celgene
- Target Recruit Count
- 75
- Registration Number
- NCT00093119
- Locations
- 🇺🇸
Abraxis BioScience Inc., Durham, North Carolina, United States
A Study of Doxil, Vincristine and Decadron (DVd) +/ CC-5013 in Relapsed Refractory Multiple Myeloma (MM)
- Conditions
- First Posted Date
- 2004-09-15
- Last Posted Date
- 2016-12-01
- Lead Sponsor
- Celgene Corporation
- Target Recruit Count
- 77
- Registration Number
- NCT00091624
- Locations
- 🇺🇸
Cleveland Clinic Myeloma Program, Cleveland, Ohio, United States
Phase I Trial of CC-8490 for the Treatment of Subjects With Recurrent/Refractory High-Grade Gliomas
- Conditions
- First Posted Date
- 2003-12-19
- Last Posted Date
- 2007-01-04
- Lead Sponsor
- Celgene Corporation
- Target Recruit Count
- 36
- Registration Number
- NCT00074646
- Locations
- 🇺🇸
Neuro Oncology BranchNational Cancer Institute, Bethesda, Maryland, United States